Purification, characterization and immunogenicity of recombinant varicella-zoster virus glycoprotein gE secreted by Chinese hamster ovary cells

Haumont, Michèle; Jacquet, Alain; Massaer, Marc; Deleersnyder, Virginie; Mazzu, Pasqualina; Bollen, Alex; Jacobs, Paul

doi:10.1016/0168-1702(95)01270-2

Cited by 44 publications

(26 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VZV glycoprotein E was selected as a candidate vaccine antigen because it is essential for viral replication and cell-to-cell spread and is a primary target of VZV-specific immune responses. [11][12][13][14][15] The antigen was combined with AS01 B because this adjuvant system promotes strong CD4+ T-cell and humoral immune responses against recombinant proteins. 16-20 Previous phase 1-2 clinical trials that were conducted in older adults and in persons with immunosuppression showed that HZ/su had a clinically acceptable safety profile and elicited a robust immune response that persisted for at least 3 years in older adults.…”

Section: Resultsmentioning

confidence: 99%

Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The results were compared with those obtained after vaccinations with purified adjuvanted recgB and recgE expressed in CHO cells, for which strong neutralizing antibody responses were previously demonstrated (13,15). The study showed that mice immunization with a plasmid encoding a VZV gB soluble form elicited the production of neutralizing antibodies with titres comparable to those obtained with the corresponding recombinant protein.…”

Section: Introductionmentioning

confidence: 84%

Differential Neutralizing Antibody Responses to Varicella-Zoster Virus Glycoproteins B and E Following Naked DNA Immunization

Massaer¹,

Haumont²,

Garcia³

et al. 1999

Viral Immunology

Self Cite

View full text Add to dashboard Cite

The only available vaccine against varicella-zoster virus (VZV) consists of the VZV-Oka attenuated but persistent virus strain. Development of a safer, subunit vaccine is therefore desirable. In this prospect, nucleic acid vaccines, expressing truncated forms of VZV glycoproteins B (recgB) and E (recgE) from which the anchor and the cytoplasmic domains were deleted, were used to immunize mice. Vaccination with recgB encoding plasmid elicited a strong and specific humoral immune response. Total IgG and neutralizing titres were comparable to those previously obtained by vaccination with purified and adjuvanted native recgB. In contrast, mice immunization with recgE encoding plasmid only induced a very weak immune response whereas we previously showed that vaccination with adjuvanted native or denatured recgE protein led to high neutralizing titres. The weakness of the immune response induced by recgE-encoding plasmid depended neither on the deletion of the anchor domain in the gE gene nor on the animal model. Analysis of antibody isotypes produced by plasmid immunizations revealed a response slightly dominated by IgG2a. Taken together, the data indicate that a VZV subunit vaccine based on adjuvanted recombinant glycoprotein E is more promising than a nucleic acid-based vaccine strategy. As regards recgB, both vaccination approaches might be appropriate.

show abstract

“…Immunoplates (96 wells; Nunc) were coated with 500 ng of recombinant gE or gB prepared and purified as described by Haumont et al [1996] and Jacquet et al [1995]. Immunoplates were washed five times with 100 l/well of TBS-T (Tris 50 mM, NaCl 150 mM, Tween 80 0.1%, pH 7.5) and saturated for 1 hr at 37°C in the same buffer supplemented with 1% bovine serum albumin (BSA).…”

Section: Titration Of Anti-ge and Anti-gb Antibodiesmentioning

confidence: 99%

“…Moreover, a recombinant form of gB was shown to induce neutralizing antibodies [Massaer et al, 1993]. For the present study, purified recombinant gE and gB proteins [Jacquet et al, 1995;Haumont et al, 1996] were used to carry out depletion experiments in order to analyze further the potential of these proteins to stimulate the synthesis of neutralizing antibodies during the course of primary infection or reactivation.…”

Section: Introductionmentioning

confidence: 99%

Neutralizing antibody responses induced by varicella-zoster virus gE and gB glycoproteins following infection, reactivation or immunization

Haumont¹,

Jurdan²,

Kangro³

et al. 1997

J. Med. Virol.

View full text Add to dashboard Cite

The purpose of this study was to compare the antibody responses to varicella-zoster virus (VZV) gE and gB after natural VZV infection and after vaccination with live attenuated OKA vaccine in order to determine the relative importance of these proteins as components of a subunit vaccine. Anti-VZV antibody titers determined by IFA were of the same order of magnitude in sera from individuals with a history of varicella and in vaccinated children but higher in individuals given booster vaccination. The titers of anti-gE and anti-gB antibodies were measured by ELISA using recombinant gE or gB as capture antigen. From these experiments, it appears that the ratio of anti-gE to anti-gB antibody is highly variable from one individual to another but relatively stable over a long period of time for a particular individual, even after a zoster episode. Neutralizing antibodies directed against gE or gB were also measured by subtracting the neutralization titers obtained before and after depletion of the specific antibodies on immobilized recombinant gE, gB, or both. This showed that, with respect to neutralization, anti-gE and anti-gB are equally prevalent in vaccinated children and that anti-gE is generally, but not always, predominant over anti-gB in VZV-infected individuals. Finally, antibodies to these two glycoproteins appear to be predominant among the neutralizing antibodies directed to other VZV antigens.

show abstract

Purification, characterization and immunogenicity of recombinant varicella-zoster virus glycoprotein gE secreted by Chinese hamster ovary cells

Cited by 44 publications

References 21 publications

Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults

Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults

Differential Neutralizing Antibody Responses to Varicella-Zoster Virus Glycoproteins B and E Following Naked DNA Immunization

Neutralizing antibody responses induced by varicella-zoster virus gE and gB glycoproteins following infection, reactivation or immunization

Contact Info

Product

Resources

About